OBJECTIVE: Mutations in ACTA1 have been associated with a variety of changes in muscle histology that likely result from fundamental differences in the way that ACTA1 mutations disrupt muscle function. Recently, we reported three patients with congenital fiber type disproportion (CFTD) caused by novel heterozygous missense mutations in ACTA1 (D292V, L221P, P332S) with marked type 1 fiber hypotrophy as the only pathological finding on muscle biopsy. We have investigated the basis for the histological differences between these CFTD patients and patients with ACTA1 nemaline myopathy (NM). METHODS AND RESULTS: Mass spectrometry and two-dimensional gel electrophoresis demonstrate that mutant actin accounts for 25 and 50% of alpha-skeletal actin in the skeletal muscle of patients with the P332S and D292V mutations, respectively, consistent with a dominant-negative disease mechanism. In vitro motility studies indicate that abnormal interactions between actin and tropomyosin are the likely principal cause of muscle weakness for D292V, with tropomyosin stabilized in the "switched off" position. Both the D292V and P322S CFTD mutations are associated with normal sarcomeric structure on electron microscopy, which is atypical for severe NM. In contrast, we found no clear difference between ACTA1 mutations associated with NM and CFTD in tendency to polymerize or aggregate in C2C12 expression models. INTERPRETATION: These data suggest that ACTA1 CFTD mutations cause weakness by disrupting sarcomere function rather than structure. We raise the possibility that the presence or absence of structural disorganization when mutant actin incorporates into sarcomeres may be an important determinant of whether the histological patterns of CFTD or NM develop in ACTA1 myopathy.
OBJECTIVE: Mutations in ACTA1 have been associated with a variety of changes in muscle histology that likely result from fundamental differences in the way that ACTA1 mutations disrupt muscle function. Recently, we reported three patients with congenital fiber type disproportion (CFTD) caused by novel heterozygous missense mutations in ACTA1 (D292V, L221P, P332S) with marked type 1 fiber hypotrophy as the only pathological finding on muscle biopsy. We have investigated the basis for the histological differences between these CFTDpatients and patients with ACTA1nemaline myopathy (NM). METHODS AND RESULTS: Mass spectrometry and two-dimensional gel electrophoresis demonstrate that mutant actin accounts for 25 and 50% of alpha-skeletal actin in the skeletal muscle of patients with the P332S and D292V mutations, respectively, consistent with a dominant-negative disease mechanism. In vitro motility studies indicate that abnormal interactions between actin and tropomyosin are the likely principal cause of muscle weakness for D292V, with tropomyosin stabilized in the "switched off" position. Both the D292V and P322SCFTD mutations are associated with normal sarcomeric structure on electron microscopy, which is atypical for severe NM. In contrast, we found no clear difference between ACTA1 mutations associated with NM and CFTD in tendency to polymerize or aggregate in C2C12 expression models. INTERPRETATION: These data suggest that ACTA1CFTD mutations cause weakness by disrupting sarcomere function rather than structure. We raise the possibility that the presence or absence of structural disorganization when mutant actin incorporates into sarcomeres may be an important determinant of whether the histological patterns of CFTD or NM develop in ACTA1myopathy.
Authors: Nigel G Laing; Danielle E Dye; Carina Wallgren-Pettersson; Gabriele Richard; Nicole Monnier; Suzanne Lillis; Thomas L Winder; Hanns Lochmüller; Claudio Graziano; Stella Mitrani-Rosenbaum; Darren Twomey; John C Sparrow; Alan H Beggs; Kristen J Nowak Journal: Hum Mutat Date: 2009-09 Impact factor: 4.878
Authors: Gianina Ravenscroft; Irina T Zaharieva; Carlo A Bortolotti; Matteo Lambrughi; Marcello Pignataro; Marco Borsari; Caroline A Sewry; Rahul Phadke; Goknur Haliloglu; Royston Ong; Hayley Goullée; Tamieka Whyte; Uk K Consortium; Adnan Manzur; Beril Talim; Ulkuhan Kaya; Daniel P S Osborn; Alistair R R Forrest; Nigel G Laing; Francesco Muntoni Journal: Hum Mol Genet Date: 2018-12-15 Impact factor: 6.150
Authors: Steven Marston; Massimiliano Memo; Andrew Messer; Maria Papadaki; Kristen Nowak; Elyshia McNamara; Royston Ong; Mohammed El-Mezgueldi; Xiaochuan Li; William Lehman Journal: Hum Mol Genet Date: 2013-07-25 Impact factor: 6.150
Authors: Michael J Rynkiewicz; Thavanareth Prum; Stephen Hollenberg; Farooq A Kiani; Patricia M Fagnant; Steven B Marston; Kathleen M Trybus; Stefan Fischer; Jeffrey R Moore; William Lehman Journal: Biophys J Date: 2017-12-05 Impact factor: 4.033
Authors: Jingjing Gu; Nick Orr; Stephen D Park; Lisa M Katz; Galina Sulimova; David E MacHugh; Emmeline W Hill Journal: PLoS One Date: 2009-06-02 Impact factor: 3.240